-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 EmvanTo8QnguIziDv6hT2gtZHRU04ECSjAj8ihatdG7In5ZBc5aZAdeHlFrook0S
 rafl/hE4S8L1r3AUmCX4Vg==

<SEC-DOCUMENT>0001104659-08-062330.txt : 20090102
<SEC-HEADER>0001104659-08-062330.hdr.sgml : 20090101
<ACCEPTANCE-DATETIME>20081006170309
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001104659-08-062330
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20081006

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Celldex Therapeutics, Inc.
		CENTRAL INDEX KEY:			0000744218
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				133191702
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		119 FOURTH AVE
		CITY:			NEEDHAM
		STATE:			MA
		ZIP:			02494
		BUSINESS PHONE:		7814330771

	MAIL ADDRESS:	
		STREET 1:		119 FOURTH AVE
		CITY:			NEEDHAM
		STATE:			MA
		ZIP:			02494-2725

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AVANT IMMUNOTHERAPEUTICS INC
		DATE OF NAME CHANGE:	19980828

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	T CELL SCIENCES INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>

<html>

<head>





</head>

<body lang="EN-US">

<div>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman"><img width="283" height="68" src="g250561dci001.gif"></font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">October&nbsp;6,
2008</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">VIA
FACSIMILE</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Mr.&nbsp;Jim
B. Rosenberg</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Senior
Assistant Chief Accountant</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Division
of Corporate Finance</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">U.S.
Securities and Exchange Commission</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Mail
Stop 6010</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Washington,
DC&#160; 20549</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.42%;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">RE:</font></b></p>
  </td>
  <td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.4%;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
  <td width="94%" valign="top" style="padding:0in 0in 0in 0in;width:94.16%;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">AVANT
  Immunotherapeutics,&nbsp;Inc.</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.42%;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
  <td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.4%;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
  <td width="94%" valign="top" style="padding:0in 0in 0in 0in;width:94.16%;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Form&nbsp;10-K
  for Fiscal Year Ended December&nbsp;31, 2007</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.42%;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
  <td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.4%;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
  <td width="94%" valign="top" style="padding:0in 0in 0in 0in;width:94.16%;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Form&nbsp;10-Q
  for the Period Ended June&nbsp;30, 2008</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.42%;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
  <td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.4%;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
  <td width="94%" valign="top" style="padding:0in 0in 0in 0in;width:94.16%;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">File
  No.&nbsp;0-15006</font></b></p>
  </td>
 </tr>
</table>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Dear
Mr.&nbsp;Rosenberg:</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">I
am responding to your letter dated September&nbsp;22, 2008 to Celldex
Therapeutics,&nbsp;Inc. (formerly AVANT Immunotherapeutics,&nbsp;Inc.) (the &#147;Company&#148;
or &#147;Celldex&#148;), which requested answers to your comments raised in your review
of the Company&#146;s recently filed financial statements contained in its above
referenced periodic reports on Form&nbsp;10-K and Form&nbsp;10-Q (the &#147;Request
Letter&#148;).&#160; The Company&#146;s responses below
correspond to the specific items set forth in the Request Letter.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="96%" style="border-collapse:collapse;margin-left:.25in;width:96.66%;">
 <tr>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.7%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1a.</font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.24%;">
  <p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:1.0pt;font-style:italic;">&nbsp;</font></i></p>
  </td>
  <td width="94%" valign="top" style="padding:0in 0in 0in 0in;width:94.06%;">
  <p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Please
  provide us your analysis under EITF 88-18 in determining that the $50 million
  in proceeds received and future proceeds should be accounted for as deferred
  revenue versus debt obligation. Please address items 1 through 6 of EITF
  88-18.</font></i></p>
  </td>
 </tr>
 <tr>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.7%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.24%;">
  <p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">&nbsp;</font></i></p>
  </td>
  <td width="94%" valign="top" style="padding:0in 0in 0in 0in;width:94.06%;">
  <p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">&nbsp;</font></i></p>
  </td>
 </tr>
 <tr>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.7%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.24%;">
  <p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:1.0pt;font-style:italic;">&nbsp;</font></i></p>
  </td>
  <td width="94%" valign="top" style="padding:0in 0in 0in 0in;width:94.06%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As
  discussed below, the Company has determined that the six criteria of EITF
  88-18 were not triggered under the Paul Royalty Fund (&#147;PRF&#148;) arrangement, and
  therefore, the arrangement should be treated as a sale and the proceeds
  received should be accounted for as deferred revenue.</font></p>
  </td>
 </tr>
</table>

<p style="margin:0in 0in .0001pt 45.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="68%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:68.92%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">www.celldextherapeutics.com</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.3%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="27%" valign="top" style="padding:0in 0in 0in 0in;width:27.78%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="37%" valign="top" style="padding:0in 0in 0in 0in;width:37.78%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.72%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="27%" valign="top" style="padding:0in 0in 0in 0in;width:27.42%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.3%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="27%" valign="top" style="padding:0in 0in 0in 0in;width:27.78%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="37%" valign="top" style="padding:0in 0in 0in 0in;width:37.78%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">119
  Fourth Avenue</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.72%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="27%" valign="top" style="padding:0in 0in 0in 0in;width:27.42%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">151
  Martine Street</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.3%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="27%" valign="top" style="padding:0in 0in 0in 0in;width:27.78%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">222
  Cameron Drive, Ste. 400</font></p>
  </td>
 </tr>
 <tr>
  <td width="37%" valign="top" style="padding:0in 0in 0in 0in;width:37.78%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Needham,
  MA 02494</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.72%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="27%" valign="top" style="padding:0in 0in 0in 0in;width:27.42%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Fall
  River, MA 02723</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.3%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="27%" valign="top" style="padding:0in 0in 0in 0in;width:27.78%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Phillipsburg,
  NJ 08865</font></p>
  </td>
 </tr>
 <tr>
  <td width="37%" valign="top" style="padding:0in 0in 0in 0in;width:37.78%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Tel:&nbsp;&nbsp;781-433-0771</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.72%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="27%" valign="top" style="padding:0in 0in 0in 0in;width:27.42%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Tel:&nbsp;&nbsp;508-742-4300</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.3%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="27%" valign="top" style="padding:0in 0in 0in 0in;width:27.78%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Tel:&nbsp;&nbsp;908-454-7120</font></p>
  </td>
 </tr>
 <tr>
  <td width="37%" valign="top" style="padding:0in 0in 0in 0in;width:37.78%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Fax:&nbsp;781-433-0262</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.72%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="27%" valign="top" style="padding:0in 0in 0in 0in;width:27.42%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Fax:&nbsp;508-742-4309</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.3%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="27%" valign="top" style="padding:0in 0in 0in 0in;width:27.78%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Fax:&nbsp;908-454-1911</font></p>
  </td>
 </tr>
</table>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\105727\08-25056-1\task3161065\25056-1-dc.htm',USER='105727',CD='Oct  7 02:14 2008' -->


<br clear="all" style="page-break-before:always;">


<div>

<p style="margin:0in 0in .0001pt 45.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt 45.0pt;text-indent:27.0pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">1.&#160; The transaction
does not purport to be a sale (that is, the form of the transaction is debt).</font></i></p>

<p style="margin:0in 0in .0001pt 45.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt 45.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Based
on the terms of the Purchase Agreement and consultation with the Company&#146;s
counsel at the time, the form and purpose of the transaction was deemed a &#147;sale.&#148;</font></p>

<p style="margin:0in 0in .0001pt 45.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt 45.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">PRF may assign any of its
obligations and rights under the agreement, without restriction and without the
consent of Celldex, to any Affiliate or member of PRF or to any Person in
connection with any financing (including any capital markets or securitization
transaction), provided the assignee has sufficient resources at the time of
assignment to adequately meet the obligations for future payments (&#147;funding&#148;)
to Celldex pursuant to the terms of this Agreement.</font></p>

<p style="margin:0in 0in .0001pt 45.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt 45.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In addition, the terms of
the agreement include rights of PRF to the purchased royalty interest in the
event of a bankruptcy by Celldex by way of a first perfected lien on and
security interest in the purchased<b>  </b>royalty
interest.</font></p>

<p style="margin:0in 0in .0001pt 45.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt 45.0pt;text-indent:27.0pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">2.&#160; The enterprise has
significant continuing involvement in the generation of the cash flows due the
investor (for example, active involvement in the generation of the operating
revenues of a product line, subsidiary, or business segment).</font></i></p>

<p style="margin:0in 0in .0001pt 45.0pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt 45.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Celldex has no significant
continuing involvement in the generation of the cash flows (product sales which
would generate the royalties).&#160; Celldex
is not involved in the manufacturing process nor is it involved in the sales
and marketing of the rotavirus vaccine product.&#160;
These activities are solely the responsibility of its partner,
GlaxoSmithKline (&#147;Glaxo&#148;).</font></p>

<p style="margin:0in 0in .0001pt 45.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt 45.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Relative to this Purchase
Agreement, Celldex and PRF also entered into a Deposit and Account Control
Agreement (&#147;Lockbox Agreement&#148;).&#160; Celldex
shall use commercially reasonable efforts to cause Glaxo to send the royalty
payments, but not the milestone payments, that are paid to Celldex under the
Glaxo License Agreement to a lockbox account.&#160;
The funds received in the lockbox account will then be distributed by
the Financial Institution and credited to each of Celldex&#146;s and PRF&#146;s accounts
maintained within the same financial institution in accordance with the terms
of the Lockbox Agreement.&#160; Other than
causing Glaxo to send its payments to the lockbox account, Celldex has no other
obligations or continuing involvement.</font></p>

<p style="margin:0in 0in .0001pt 45.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt 45.0pt;text-indent:27.0pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">3.&#160; The transaction is
cancelable by either the enterprise or the investor through payment of a lump
sum or other transfer of assets by the enterprise.</font></i></p>

<p style="margin:0in 0in .0001pt 45.0pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt 45.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The term of the agreement is
through the last of the expiration of the patents related to the License
Agreement with Glaxo (12/2012).&#160; PRF
however, has the option to terminate the agreement in the event that the U.S.
Commercial launch </font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\105727\08-25056-1\task3161065\25056-1-dc.htm',USER='105727',CD='Oct  7 02:14 2008' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt 45.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">date of the product does not
occur on or before December&nbsp;31, 2009, by providing notice to Celldex
within ten (10)&nbsp;business days after December&nbsp;31, 2009.&#160; There are no termination payments required to
be paid back to PRF if PRF exercises the option to terminate the
agreement.&#160; In addition, there are no
other cancelable clauses that would allow either party to terminate the
agreement through payment of a lump sum amount or other transfer of assets.</font></p>

<p style="margin:0in 0in .0001pt 45.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt 45.0pt;text-indent:27.0pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">4.&#160; The investor&#146;s
rate of return is implicitly or explicitly limited by the terms of the
transaction.</font></i></p>

<p style="margin:0in 0in .0001pt 45.0pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt 45.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Although PRF&#146;s purchased
share of the royalties drops to 7.5% from 100% after reaching 245% of their
purchase price paid to Celldex, this does not effectively impose a limit to the
earn-out amounts that PRF may receive.&#160;
The revenue stream from which PRF&#146;s rate of return is earned is
unlimited i.e. worldwide product sales of rotavirus vaccine and, as such, PRF&#146;s
potential rate of return is unlimited.</font></p>

<p style="margin:0in 0in .0001pt 45.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt 45.0pt;text-indent:27.0pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">5.&#160; Variations in the
enterprise&#146;s revenue or income underlying the transaction have only a trifling
impact on the investor&#146;s rate of return.</font></i></p>

<p style="margin:0in 0in .0001pt 45.0pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt 45.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">PRF&#146;s rate of return is
expected to fluctuate through the terms of the agreement depending upon the
amount of royalty revenues that may be generated from Rotarix&#174; worldwide sales
made by Glaxo.</font></p>

<p style="margin:0in 0in .0001pt 45.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt 45.0pt;text-indent:27.0pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">6.&#160; The investor has
any recourse to the enterprise relating to the payments due the investor.</font></i></p>

<p style="margin:0in 0in .0001pt 45.0pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt 45.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">PRF has purchased the
royalty interest from Celldex and has no recourse to Celldex irrespective of
the level of sales made by Glaxo.&#160; PRF
has protected its purchased royalty interest in the event of a bankruptcy by
Celldex by way of a first perfected lien on and security interest in the purchased<b>  </b>royalty interest.</font></p>

<p style="margin:0in 0in .0001pt 45.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt 45.0pt;text-indent:-27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1b.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><i><font size="2" style="font-size:10.0pt;font-style:italic;">Please provide us your analysis under SFAS 2 in
determining that payments made by you under this arrangement, and that of
Cincinnati Children&#146;s Hospital (&#147;CCH&#148;), should be classified as research and
development costs versus cost of revenue.&#160;
Refer to paragraph 11 of SFAS 2.</font></i></p>

<p style="margin:0in 0in .0001pt 45.0pt;text-indent:-27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt 45.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The
Company has determined that the royalties paid to CCH represent contingent
purchase price arrangements for the acquisition of technology, specifically, an
interest in intellectual property, and therefore, should be properly classified
as research and development costs on the Company&#146;s Statements of Operations in
accordance with paragraph 11 of SFAS 2.&#160;
In Note 9 of the Company&#146;s 2007 Form&nbsp;10-K, the Company disclosed
amounts &#147;related to AVANT&#146;s retained interest in Rotarix&#174; net royalties which
were not sold to PRF, which also corresponds to the amount payable by AVANT to
CCH. As such a corresponding amount is recorded as royalty expense and included
in research and development expense.&#148;&#160;
Note 10 of the Company&#146;s most recently filed Form&nbsp;10-Q also </font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- SEQ.=1,FOLIO='3',FILE='C:\JMS\105727\08-25056-1\task3161065\25056-1-dc.htm',USER='105727',CD='Oct  7 02:14 2008' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p style="margin:0in 0in .0001pt 45.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt 45.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">disclosed
that the non-PRF portion of Rotarix&#174; royalty was recorded as product royalty
revenue and was offset by the same amount of royalty expense recorded as
research and development expense.</font></p>

<p style="margin:0in 0in .0001pt 45.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt 45.0pt;text-indent:-27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1c.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><i><font size="2" style="font-size:10.0pt;font-style:italic;">Provide us the facts and
circumstances contributing to the elimination of the $47 million of PRF
deferred revenue existing at December&nbsp;31, 2007, but not included in the March&nbsp;31,
2008 Consolidated Balance Sheets.</font></i></p>

<p style="margin:0in 0in .0001pt 45.0pt;text-indent:-27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt 45.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The
Merger of AVANT and Celldex was accounted for as a reverse merger with Celldex
deemed the accounting acquirer.&#160; In
accordance with EITF 01-3, &#147;Accounting in a Purchase Business Combination for
Deferred Revenue of an Acquiree&#148;, the Company determined that there were no
remaining legal performance obligations to PRF for the combined company
post-merger, and therefore, no liability should be recorded in connection with
the purchase accounting for the Merger.</font></p>

<p style="margin:0in 0in .0001pt 45.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt 45.0pt;text-indent:-27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><i><font size="2" style="font-size:10.0pt;font-style:italic;">You
state &#147;in connection with the Merger, AVANT recorded $9.8 million as an other
current asset, which represents the present value of this milestone payment
adjusted for probability of success.&#148;&#160;
Please provide your analysis in determining the &#147;probability of success&#148;
valuation of the $9.8 million contingent payment and basis for recording it as
a current asset.</font></i></p>

<p style="margin:0in 0in .0001pt 45.0pt;text-indent:-27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt 45.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The
Company determined that the expected payment was based on an existing
contractual arrangement with a high probability of receipt and that, as such,
it reflected a probable future economic benefit to the Company.&#160; At the time of the Merger, Rotarix&#174; had been
approved in approximately 100 countries worldwide, including the European
Union, where it had been approved in 2007.&#160;
Thus the Company concluded that there was a very high probability for
the approval of Rotarix&#174; in the U.S. (and, indeed, it was)&#160; For purchase accounting, the PRF milestone
payment was viewed as a financial asset, and classified as current, considering
that the near-term expected payment was probable.&#160; The anticipated event has occurred (Rotarix&#174;
was approved by the FDA in April&nbsp;2008 and launched by Glaxo in the U.S. in
August&nbsp;2008) and, as expected, the Company collected the full amount of
the $10 milestone from PRF on October&nbsp;1, 2008.</font></p>

<p style="margin:0in 0in .0001pt 45.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The
Company acknowledges that:</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The Company is responsible for the adequacy
and accuracy of the disclosure in the filings;</font></p>

<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Staff comments or changes to disclosure in
response to staff comments do not foreclose the Commission from taking any
action with respect to the filings; and</font></p>

<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The Company may not assert staff comments as a
defense in any proceeding initiated by the Commission or any person under
federal securities laws of the United States.</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- SEQ.=1,FOLIO='4',FILE='C:\JMS\105727\08-25056-1\task3161065\25056-1-dc.htm',USER='105727',CD='Oct  7 02:14 2008' -->


<br clear="all" style="page-break-before:always;">


<div>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We
trust this letter is fully responsive to the Request Letter.&#160; Please do not hesitate to contact me if you
have any questions relative to this matter.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Very
truly yours,</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman"><img width="156" height="56" src="g250561dci002.jpg"></font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Avery
W. Catlin</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Senior
Vice President and</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Chief
Financial Officer</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.58%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">cc:</font></p>
  </td>
  <td width="94%" valign="bottom" style="padding:0in 0in 0in 0in;width:94.42%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Anthony
  S. Marucci, Chief Executive Officer</font></p>
  </td>
 </tr>
 <tr>
  <td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.58%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="94%" valign="bottom" style="padding:0in 0in 0in 0in;width:94.42%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Anthony
  O. Pergola,&nbsp;Esq.</font></p>
  </td>
 </tr>
</table>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- SEQ.=1,FOLIO='5',FILE='C:\JMS\105727\08-25056-1\task3161065\25056-1-dc.htm',USER='105727',CD='Oct  7 02:14 2008' -->


</body>

</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g250561dci001.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g250561dci001.gif
M1TE&.#EA&P%$`'<`,2'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E`"'Y
M!`$`````+``````;`40`AP``````````,P``9@``F0``S```_P`S```S,P`S
M9@`SF0`SS``S_P!F``!F,P!F9@!FF0!FS`!F_P"9``"9,P"99@"9F0"9S`"9
M_P#,``#,,P#,9@#,F0#,S`#,_P#_``#_,P#_9@#_F0#_S`#__S,``#,`,S,`
M9C,`F3,`S#,`_S,S`#,S,S,S9C,SF3,SS#,S_S-F`#-F,S-F9C-FF3-FS#-F
M_S.9`#.9,S.99C.9F3.9S#.9_S/,`#/,,S/,9C/,F3/,S#/,_S/_`#/_,S/_
M9C/_F3/_S#/__V8``&8`,V8`9F8`F68`S&8`_V8S`&8S,V8S9F8SF68SS&8S
M_V9F`&9F,V9F9F9FF69FS&9F_V:9`&:9,V:99F:9F6:9S&:9_V;,`&;,,V;,
M9F;,F6;,S&;,_V;_`&;_,V;_9F;_F6;_S&;__YD``)D`,YD`9ID`F9D`S)D`
M_YDS`)DS,YDS9IDSF9DSS)DS_YEF`)EF,YEF9IEFF9EFS)EF_YF9`)F9,YF9
M9IF9F9F9S)F9_YG,`)G,,YG,9IG,F9G,S)G,_YG_`)G_,YG_9IG_F9G_S)G_
M_\P``,P`,\P`9LP`F<P`S,P`_\PS`,PS,\PS9LPSF<PSS,PS_\QF`,QF,\QF
M9LQFF<QFS,QF_\R9`,R9,\R99LR9F<R9S,R9_\S,`,S,,\S,9LS,F<S,S,S,
M_\S_`,S_,\S_9LS_F<S_S,S___\``/\`,_\`9O\`F?\`S/\`__\S`/\S,_\S
M9O\SF?\SS/\S__]F`/]F,_]F9O]FF?]FS/]F__^9`/^9,_^99O^9F?^9S/^9
M___,`/_,,__,9O_,F?_,S/_,____`/__,___9O__F?__S/___P$"`P$"`P$"
M`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"
M`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"
M`P$"`P$"`P$"`P$"`P$"`P$"`PC_``$('$BPH,&#"!,J7,@PH0L:#R-"=-&P
MHL6+#!5@W$A0(\>/($.*'$E28`(:)Q6@7'DRY<J2,`724*G2H,N8-F>BQ,FS
MI\^?*A\J<"$4HLZB17]R3&J0Z$R*0)TJG4JU:L*5*EVV9(F5ZTFK%;,>W)I`
M*4NP:-/R-"HQJ$*V<-4B#`K1(%NS$N7J74C6Z\ZJ7&O2L.AW+T&N.;_^)&NX
ML<"A$H4Z54GCZ52C"8@"@(KQ)-/&*#D3=*HYZD/'<KOV71WX;TRO(K4.;BPV
ML>N>9U&CA1N9M^_>,2.3I'MZ;UN[$:?FU6W5+^OGA4DR+CE=+^*"6R^W9$Z5
M+N2GDL.#_Q__O>9(\#B]BTZK\^#D]>FE<E_LO#YTUB)U*H8)&^/?_QO5AEUN
M%_U7UE7;772@@?,UY1MQ1D&(%%P2@G0<3G%9U%MO'C5$'')U$2;A42`6U]!O
M$8:X4!=C"-2%2"8FE)5]--[77V<$8I@@7_K5-^.)V0VXWUNR04=0=0H52>-"
M9(Q!1A>(Y,"15@M]X51F$V)Y5&A93H;9E32TTIF7/DFV4(2D?<GA;&=FYEY$
M\'7TT);E5?9490<"\%U&*5;VW9Q<SK1B%UT\B=%#6"Z$#39>U.BHC0E\T<JB
M!2*Y5IX'V2?3@K*9-]=M`UE:4&$,`J#:IJ`:-&-M#*ZF$!DY//\)JT6B%K3H
MHH-LN2&*N_:6@!>W4EJ1<'O]MM"&#D58HHR\-;3<<ID"=VRS"3TY1J$O,B0M
M0L'B^NBW9`TR:;"$!9E:K5?-B.EAYH;Z$D(W,J3DN@/U2"^1.1HD:Z%2)GD=
M0N-VFXA.Y;TG7L'B)3!(M[>&A9EU2&UDIZ=V43S0>V^VAY%Z,<HI%$?EO4HH
MMF^%G!`B`0?;"A:0@IL(PXLB4E%7>J'KX;NJI@J`J/'2VK-)^9:+,T*PRMKO
M@#\J="T9*=_J"A8T/2CUAB_#C,BUSAI5;'(@9=C17:-R75#$'T'HH-@<D<@D
MBRQ&JVRU_))1=;>M?-$R="ZX`C,V+,;_>C1"-FLW]$8\MPOTD(?K+/2.]=X$
M4N`"%5WHD?\FA"VA8\S=[1=9>8FHYUP^I#?#LS0YLJ$*F9R6EAV6_3:[<9(&
MGUOY[3G:9Q^AV="3+))1K^H(Q1IWH8C`W,H@=W-%P]ZT8"NY[_A:W!SCN3O^
M];V6&EX]J)"?*""3PD.?]$+7EL_V&,7#/,B(O;J`Q=ZMG"__M!V#!6U(8%_\
M>KUHR]1_VO<32`"7DC^%8&L,"-S,__0UO*+%"E@P2T3RW@>S683O@M!#T."J
M\AQ4):@_T6G<!@U7N:Y1SU6FF@X(\=.0!IJDA4L[W<B<M+>!D<=@+H`@PQ)Q
MN1[R+G7[`TN=_XKBIS[1:6*3J1B;;F>9PT!F.%ICHG<F9L0I%A%WY+M<BRSR
M/`QB:V^N0%1]="@P+W8Q>DODR?=0M2K5]*B-G0+5&A.WKO'A[X2MB:,>WZ@X
MRSVO(DZ2G_G,-PN8N0(B$%+)PJPFR$9B#2'$ZLF'^$>AJ55R3>N9Y&'Z%\F0
M!/"2H&R+)>-D0&ME:R$8])O1)%=(F.&)*XND6Y0<N$I53BXAVN,/'JFGHQ'Z
M$G%3RE<N.3B;X<'0AVSC'=N:=BLL!(J9V"@=,F-(*&L="XLEP5A!GJB=V,%I
M5+03B>TNALWNE`:!IEQ1%U?9P!RTDF&OU-RM6C'+=K)S5O[BI72"%O^T].@L
M>QM,VR[[Z),VNDAR2G.D0J\EST4E0B44I)LI!ZE0U"5K@?E9X`"#$T13_<]K
MN1O@1G^R+02:+R%F3*G1&IHKA3&L%>NTIPOQI4\3!K2$$N,E3K77/1[I=)B+
M\ZG&!E)+HLFPFD?MX;5>.I0O[!"92(WJ`4^9KB26!'@#44](Z)(IZ2FPB1X3
MU$?$TU45$7`B0#2307K'MH/(-*8.1-D\L=%2IV(C8(BXITKC!J1^!BB@[JII
M0X8YQYWQLZ>VT:<=_1,XFAFU:`>AJ&0=288=$B6BM%A4_";+69)YKX`2ZZ1[
M.IJUC^7LHQC=$@!!2DFO9BV<9XMB0LQG48'_I'*=MH05(@HYJ4G5M;=WQ49>
M;TM<654$A3GU*[N4"SB<IO"7:0PL8)NK+L4Y5ZCW$J%@B<K7@B13AM2<ZI.P
MH;=6N,(5$G3?7<_K4/&"=YK^J9.&3%6PSZI57KJ#EYN:\LW1LDY;])W-.+>9
M(@V1;2QD.J8U"0+7O<H5N+\-[J3R^M:4)C<[_V3C=/7+W)T9UGH'*:S-ME)8
M[1JHC_.B*4%_AM)5$B20G95L9<U+XT$\!`NNH'%Y%[K0U?:*5Z`]T8^''-W1
M=#3(8P-RK_17/R,3><E7&6DIS\?=!NL5$9E-1(YIT:A(:=F\+QNN7L?\MTK9
MZULV94UU2[Q<Z0'5_XEYS.-RLSOG.)-XQ8@M2/AN^5VI*E.92SUO*P:]/O?E
M>-""AJJB?_BX-/G)2X^^ZIRL2*+6E:S(VLP(Z*:H*OD<*\`3TJI"$OR1/@/`
MRO;,`<I<,0A6NZ++7]!RJQ=&852?D22:,A5N5$AGJW"JPP+],+!#M2F1]`N?
M,:;L75N1"&;;F`988/;Q>LOCR3;HVMC.MKY465Q^K5I<K79FI,#-:N'B]MRW
MU+:ZUXV::;I[O,X>A+PS$VUYBRO'[D5J>&O+[G[[&RP59N>WIRWN+(#[>.8.
MN#'_S?"&*R79@ZRLO>5MI<I,O-6;K3:5'<[QCI-DKUW<[:OEG0AQ?T$0)/\7
MA+E!'CZ/N_SE'.FSHI=Z<<X]Y.+X_G-2%PQSF%"UYR#Y.4EL[3>4U6T06$`Z
M2K#P!:0/`EBU9CG0-Y+N@51]ZL$C&ADRB!.-T_#B6)B3O9N.;X@+'>M3]NXC
MT6ZY+8)E7[3,P1A4R>RD)QU/6;`[TH4[][G'W6ALY^+5`1"KP%>KS%:1.2)0
MEHA9O$S>3/]"%C)#`Z1_H>FM</PL$)$("NO[[(97^P$+HG.W$^1%C/:NB]:^
M^D`*O6T`(-G9,9=ZJ[_>]J-7/>EE[]8$@CYRSHM5\8![/+WC"0MZQS%P]=;.
MT#/DUE;'IW$97'C(ZMEWUB?JL84.]PMN.W*(QR?_\#,(?8$XB2`6KK*4SJ\T
M!+*M>)9GNOR_@/PYT?_^\U<^;7_O?.]R?2"L9U*G9U%75SYK%8#<!WL`((#1
M1U6UQ8"K=X!K]7\\QWY6YW8)M#:R4EEV1W_QERM+)W\?R'0+XWW]MSMG5W@#
MX3<K6%O3=U"(YU;_%WL4Z(`_QX*V)7ZG%G[A]W.#1WHQR!#OYPKXAWSTAWQ0
M\Q!'*']&&&W29'HGJ$X)>'I02"@N@GI6&($(887I-(`2:'Z7<X552%6>=84S
M>&JG](/ZXGZQ5Q%%4SSS1P/W)X>OQ'1R:(?WMS#\$H5N.'A5IX+:YV)<!XC;
MAGV$B(;?EX/V!(0,]H?\_W90W.6&L>(D08@0Q;.$2)B)<Y*)G*A_?&@19;AZ
M/Y>!"PB%D35[#^B#_%9U"H@0I*B%5#B!`SB*[6>*#&&'SO0%-)`%<H@HSL2+
MNIB+N^@%GW@1CTAX%/@WJWA]![&*-3B(.OB"-'@TAZB#X,=`_H=^T:B,_(<0
M2`AMG3@4X/B-G%B,QMB*B`B`56@H,G1ZH+=@;46%HU=[:)@M?KA%[6A[/`=\
ML=@V#^AZYF>+9P*,NTB'O+@2!IF0NFB.H-@DV=B"!C&)TIB#6]A]34)^VS>1
MXT>)#'1/:X4(HSB(-.@\$TB2:5,O6"`3%Y.2NB83+,F07>>*!K0B%SB+5K<B
A`AVIA>BH-#/9DS#YDR"AD4`YE">XDT1YE*%WC!T7$``[
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g250561dci002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g250561dci002.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MP``+"``X`)P!`1$`_\0`'P```04!`0$!`0$```````````$"`P0%!@<("0H+
M_\0`M1```@$#`P($`P4%!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$(
M(T*QP152T?`D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%56
M5UA96F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBI
MJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W
M^/GZ_]H`"`$!```_`/?J***********Q_%/B2T\)>'KG6K^.:2VMR@=85!;Y
MF"\9([FM6&59X8Y4^XZAESZ$9I]%%%%%%%<C/XSN+[6)],\+Z4-7DM'*7ER]
MQY%O`_\`<W[3O;U"@X[T^U\<6T&H/IOB2V&@WRH9$^TSJ8)T'4QR\`XXR"`1
MGI75*P90RD$$9!'>EHHHKFO$/CC2?#VH0:8Z75]JDXW1V%A%YLQ7^\1D`#W)
M%3:'XQTG7;R6PB-Q::E"-TEC>PF&=5_O;3U'N,BM^L3QCI8UKP9K.G%<F>TD
M5>,_-M)7]0*Y+PC\0M$T_P"''AV;5]33[9):K$MN@,D\A0E.(TRQ^[UQ6E'X
MI\6:QDZ+X.>V@/W;C6;D6^?^V2AG_/%6U/Q`VEF7PQG'"!I^O^]C^E,D\4ZY
MHX9_$'AF5;1?O7FES?:E7W:/:K@>X!KHM+U;3]:L$OM,O(;NU?[LD39&?0^A
M]CS5RBBN-^(&JWJV5IX=T64IK6LR>1$Z<F"$?ZV4^@"\9]2,5T.A:)9>'=%M
M=*T^/9;VZ;1ZL>[,>Y)Y)K,\=^%[3Q=X2OM.N8!)+Y326S8^:.4`[2#]>#Z@
MUE_"'59]7^&6DRW3,T\"O;,S=3L8J/\`QT`5W%%%<WXZ\4?\(EX8FU"*'S[R
M1UM[.#_GK,YPH_F?PJOX'\'CPW92WE_)]KU_4#YVH7C\LSG^!3V1>@%'C[PT
M^MZ+]MT]C!KNF9N=/N4X8.HSL/JK#@CIS5SP?XHA\4>#;'7B%@$L1,ZL<"-U
M)#\GH`0>O:N:.N:_\0998/"\O]D^'T<QR:S(FZ6YQP1`AZ#_`&S^%5O@MH&G
M:7X;NV2R@&I6^H7%I-=%/WK['P`2>5XQP.*].HHKB/$>B7>@7TOBSPRA$Z?/
MJ6FJ<1WT8'+`=!*!R&[]#FNJTC5;/7-(M=4L)?-M;J,21M['L?0CH1ZBKM%<
M)X%B_M[6]9\:3J";J9K&PX^Y:Q,5R/\`><$GZ"N[ILA"QLS'``))KR3]G[5H
MKOPGJ6G(FU[.^9LYSN63D$_D1^%>NT4$X&3TKSS75_M_XQ>'])+;K72+1]5E
M4=#(3LCS]#S7H=%>2_"S2[76/"/BW0KQGFL&UFYM]JDH=A"],<BO2=#T2S\/
M:3!IEAYWV:!0J"65I"!Z9)X'L.*Y'X<$VNM^-]+8Y:'6WN!D#.)E##^5=_11
M17"?#U1IFL>+?#D;?Z/I^HB:W3/$<<Z"3:/8'=^==W6/XLN9+/P?K5S$',D5
MC,Z^7][(0XQ57P%9I8?#_P`/V\9!5;"$Y`QDE02?S)KHJ0@,"K`$'@@]Z\S^
M%FF)HWB+QIIL11+>TOUC@A5<>7&=TB\]3]_OZ5VOB?Q-IWA'0I=8U0RBUC94
M(B7<Q+'`P*U+>XBN[:*YA;?%*@D1O52,@_E1/!%<V\EO.@DBE0HZ-T92,$'\
M*\B^$F@#1/'GC.U-S)*M@\5I;K*Y9EA)9U'/;&/UKV&L_7-4BT/0;_59B/+M
M+=YCGOM!./QZ5C?#NXN;_P`$6&J7MG:6MYJ`:YF6UA\I6+$X8CN2NW)KJ:\_
MT(+8?&OQ3;?=^WV%K=@$?>V90D'\:TO$/Q$T?PSXLTKP_J`F$VHC*RJ,K'EM
MJ[N_)R..E==117#>"`+OQAXXU5$81RZC':JQ/#&&(*WZDUW-4]6LCJ>C7U@'
MV&ZMY(0Y&=NY2,_K7,_#?5%D\,VV@W>8-9T>);2[M9&^<;!@./5&&""..?:N
MNGGAM86FN)HXHEY9Y&"@?4FL)O$3:LQMO#B_:F.0VH%<VT/ON_Y:'_97\2*Y
M?0K6'P;\5M0TV25C;Z_9I=0SS,2TMQ$2)`2?XB&W8'`'2JWCG3F^)6KMX>LY
MW;2-,@DN+N:W;A[HJ1%%NP02,[B.V><&MGPIXLM+3X0:?KVH3+LL[$)/V/F1
M_)LQ_>)`&/4UL^%O%4?B.":.:RFTW4[;;]IL+@@O&&&58$?>4CH?J.U>8>']
M?NM(^)GB_P`1-#]J\.37ZV-W=Q@LUNR+\K8'5!]UO3(->P+KFD/:+=KJED;9
MAD3"X38?QSBO-_BIKMSX@\!:M:^'+9KVQC"&\OESY94.,I$<?O&[DC@`'G/%
M7[?Q]J-CH\6K-X0NK;PK`J1^>T@6X2,8'F^0`?W8^N<<XQ7H,5[:SV4=[%<1
MM:RHLB2[AM96Z'/OD5POB21=)^,/A747.V&_M+G3Y'/12,2+D^Y_E6#;>'(?
MB?-XPUEW"6UVR6.D7)&=@@Y\U?8R?IFMC2?$_P`0)+2*&3P=NFL(@E\]S<B(
MW3CC,!P0V0,Y.!DXS75:%XOTC7Y'MH)7M]1C'[[3[M#%<1?5#R1[C(]Z;XP\
M36_A7P_->O\`/=O^ZL[8<O<3MPB*.IYQGVJ/P)H,OASPA96-T=U\X:>[?^]-
M(2S_`)$X_"NCHK*U;PUHVNR1R:EI\4\T0Q'-RLB#T#J0P'MFJ<'@;PS!()#I
M$$[#H;HM/CZ>83BN@551`B*%51@`#``K(\1^%M&\66"66M62W,*.)$^8JR-Z
MAE((]*T+&PM-,LHK.QMHK:VB&U(HE"JH^@K`3X?^'8];?5%M'WO-]I-MYS?9
M_._YZ^5G;O\`?'OUJ;Q)X5379(KVSO[C2M7@1HX;^V`+!&ZHRGAE[X/0\C%3
M^%?#%EX2\.V^CV19XX\F263[TKDY9F]S_+`IQ\)^'#/YYT#2S+G=O^R1YSZ]
M.M:ZJJ($10J@8``P`*1T26-HY$5T<%65AD$'J"*YK3?`FDZ7(J1RWDUC$_F6
MVGSS;[>W;.<HOL>@8G';%.\;>"=/\<Z3#87\T\'DS":.6`@,IP01SV()K<T[
M3[32=.M]/L85AM;=!'%&HX4"K-96L^&]&\0(BZKIT-RT?,<C#$D?^ZXPR_@:
BSM.\`Z!INKQZJ(KJZO801!+>W<EP80>NS>3M^O6NFHK_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
